Q-omics provides the consensus-scored ALKBH3 profile across patient tissues and cancer cell-line models. ALKBH3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ALKBH3 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ALKBH3 RNA expression shows 18,663 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, HNSC, and ACC as cancer lineages where ALKBH3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALKBH3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALKBH3 survival associations across molecular data types. ALKBH3 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALKBH3 RNA expression–survival associations across cancer types. High ALKBH3 expression shows unfavorable associations in KICH, BLCA, ACC and KIRP, but favorable associations in KIRC and CHOL. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for ALKBH3 RNA expression.
This table summarizes ALKBH3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ALKBH3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALKBH3 shows lower tumor expression in UCEC, BRCA and THCA and higher tumor expression in HNSC, COAD and KIRC. The HNSC box plot shows higher ALKBH3 RNA expression in tumor versus normal tissue (log2 FC = +0.603, t-test p < 0.001).
This table shows molecular features associated with ALKBH3 in patient tissues and cancer cell lines. In patient samples, ALKBH3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ALKBH3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
